SMALL CAP MOVERS: Summit Therapeutics lifted by US deal; Nu-Oil jumps 400% but Xcite and Stanley Gibbons plunge further

For the junior biotech the Holy Grail is taking a drug all the way from the lab to the market – in the US they call it hitting a home run and the achievement is usually transformational.
Unfortunately, very few home runs have been hit here in the UK, even though we have a very active drug development sector.
That’s because the costs of developing a new treatment are prohibitive as they can run to hundreds of millions of pounds – and of course success is not guaranteed.
Often the next best thing is to find a big brother with pockets deep enough to fund the work required to get a new... read more

7 October 2016 in Business, Views: 36
Source: Daily Mail

    News Widget for Webmasters

    Bring Eugene's son back home immediately

    Realtime News


    Mo Tu We Th Fr Sa Su
            1 2 3
    4 5 6 7 8 9 10
    11 12 13 14 15 16 17
    18 19 20 21 22 23 24
    25 26 27 28 29 30